We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Columbia Sportswear Reveals Plan to Bolster China Business
Read MoreHide Full Article
Columbia Sportswear Company (COLM - Free Report) revealed intentions to solidify operations in China by purchasing the remaining 40% stake of its joint venture business. The Columbia brand’s joint venture business in China, Columbia Sportswear Commercial, was established in 2014 in collaboration with Swire Resources Limited. The company expects to complete the buyout of the remaining stake in the venture by Jan 1, 2019, post clearances on several regulatory norms.
China Operations Bodes Well
The Columbia brand achieved significant growth in China, on the back of its strategic partnership with Swire Resources. In fact, the venture generated sales worth $168 million during 2017, while margins were in the low-teens. At the end of 2017, the venture operated 86 retail stores in China and had agreements with 50 wholesale dealers operating across 750 retail locations to support its e-commerce sales.
In fact, the company’s consistent success and well-spread operations in China propelled it to undertake measures to further solidify its footing in the nation. For 2019, management projects sales growth in the region in high single-digits. Notably, Columbia Sportswear is on track to expand its dealer-based and direct retail operations in China. Further, with continuous support from Swire Resources, Columbia Sportswear expects to bolster its business in Macau and Hong Kong.
Will Expansion in China Bear Fruit?
The ongoing tariff war with China has spurred a lot of worries for U.S. companies, who operate in the region. However, it’s not quite apparent if such headwinds will dent Columbia Sportswear’s operations in China.
Nevertheless, management is impressed with the sturdy business advancement in the region and expects continued growth in the forthcoming periods, driven by well-established distribution networks and partnerships. Further, management states that acquiring the remaining stake of the China joint venture is in sync with its strategy to continue investing in markets with high growth potency. Moreover, expanding in China provides Columbia Sportswear the advantage of utilizing the nation’s strength in digital wholesale and e-commerce channels.
Apart from China, Columbia Sportwear’s European business has been growing rapidly. Clearly, the company’s well-chalked strategic endeavors have enabled it to develop a robust international business. These efforts combined with benefits from Project CONNECT and unique marketing initiatives have bolstered Columbia Sportwear’s position in the active lifestyle apparel and accessories space, which continues to fuel investors’ optimism in the stock. Evidently, shares of this Zacks Rank #2 (Buy) company surged 33.6% in the past six months, outperforming the industry’s gain of 19.3%.
G-III Apparel came up with an average positive earnings surprise of 41.5% in the trailing four quarters. It has a long-term earnings growth rate of 15%.
Ralph Lauren pulled off an average positive earnings surprise of 10.4% in the trailing four quarters. Also, it has a long-term earnings growth rate of 10.2%.
Tailored Brands delivered an average positive earnings surprise of 50.9% in the trailing four quarters. It has a long-term earnings growth rate of 16.5%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Columbia Sportswear Reveals Plan to Bolster China Business
Columbia Sportswear Company (COLM - Free Report) revealed intentions to solidify operations in China by purchasing the remaining 40% stake of its joint venture business. The Columbia brand’s joint venture business in China, Columbia Sportswear Commercial, was established in 2014 in collaboration with Swire Resources Limited. The company expects to complete the buyout of the remaining stake in the venture by Jan 1, 2019, post clearances on several regulatory norms.
China Operations Bodes Well
The Columbia brand achieved significant growth in China, on the back of its strategic partnership with Swire Resources. In fact, the venture generated sales worth $168 million during 2017, while margins were in the low-teens. At the end of 2017, the venture operated 86 retail stores in China and had agreements with 50 wholesale dealers operating across 750 retail locations to support its e-commerce sales.
In fact, the company’s consistent success and well-spread operations in China propelled it to undertake measures to further solidify its footing in the nation. For 2019, management projects sales growth in the region in high single-digits. Notably, Columbia Sportswear is on track to expand its dealer-based and direct retail operations in China. Further, with continuous support from Swire Resources, Columbia Sportswear expects to bolster its business in Macau and Hong Kong.
Will Expansion in China Bear Fruit?
The ongoing tariff war with China has spurred a lot of worries for U.S. companies, who operate in the region. However, it’s not quite apparent if such headwinds will dent Columbia Sportswear’s operations in China.
Nevertheless, management is impressed with the sturdy business advancement in the region and expects continued growth in the forthcoming periods, driven by well-established distribution networks and partnerships. Further, management states that acquiring the remaining stake of the China joint venture is in sync with its strategy to continue investing in markets with high growth potency. Moreover, expanding in China provides Columbia Sportswear the advantage of utilizing the nation’s strength in digital wholesale and e-commerce channels.
Apart from China, Columbia Sportwear’s European business has been growing rapidly. Clearly, the company’s well-chalked strategic endeavors have enabled it to develop a robust international business. These efforts combined with benefits from Project CONNECT and unique marketing initiatives have bolstered Columbia Sportwear’s position in the active lifestyle apparel and accessories space, which continues to fuel investors’ optimism in the stock. Evidently, shares of this Zacks Rank #2 (Buy) company surged 33.6% in the past six months, outperforming the industry’s gain of 19.3%.
Greedy for Textile-Apparel Stocks? Check These
Investors interested in the same sector may consider investing in companies such as G-III Apparel Group, Ltd. (GIII - Free Report) , Ralph Lauren Corp. (RL - Free Report) and Tailored Brands, Inc. , all carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
G-III Apparel came up with an average positive earnings surprise of 41.5% in the trailing four quarters. It has a long-term earnings growth rate of 15%.
Ralph Lauren pulled off an average positive earnings surprise of 10.4% in the trailing four quarters. Also, it has a long-term earnings growth rate of 10.2%.
Tailored Brands delivered an average positive earnings surprise of 50.9% in the trailing four quarters. It has a long-term earnings growth rate of 16.5%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>